Amgen today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis (carfilzomib) for injection in combination with Revlimid (lenalidomide) and dexamethasone (KRd) for the treatment of patients with multiple myeloma who have received one to three prior lines of therapy.

“The expanded indication of Kyprolis provides patients with relapsed multiple myeloma a new therapeutic option, helping to address a real unmet need for this common blood cancer,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “The approval of a second indication for Kyprolis in just three years demonstrates that it is becoming a critical component in the treatment of multiple myeloma, and underscores our commitment to advancing care for patients with this challenging disease.”

For more details; go to: http://www.onyx.com/view.cfm/743/fda-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma